GlaxoSmithKline PharmaceuticalsNSE:GLAXO -0.50%73 Interest Coverage is 553.70 as of Mar. 2026, which is 20% above its 10-year median of 461.38. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,610.20 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, GlaxoSmithKline Pharmaceuticals ranks better than 90.35% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. GlaxoSmithKline Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was ₹3,378 Mil. GlaxoSmithKline Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was ₹-6 Mil.
GlaxoSmithKline Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 553.70.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. GlaxoSmithKline Pharmaceuticals Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Interest Coverage or its related term are showing as below:
NSE:GLAXO'
s Interest Coverage Range Over the Past 10 Years
Min: 102.65 Med: 461.38 Max: 2519.8
Current: 455.22
NSE:GLAXO's Interest Coverage is ranked better than 90.35% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs NSE:GLAXO: 455.22
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
GlaxoSmithKline Pharmaceuticals Interest Coverage Related Terms
GlaxoSmithKline Pharmaceuticals Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:GLAXO vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Interest Coverage of 553.70 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is 20% above median its historical median of 461.38. Over the past decade, GlaxoSmithKline Pharmaceuticals' Interest Coverage has ranged from 102.65 to 2,519.80. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #66 out of 684 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is GlaxoSmithKline Pharmaceuticals' Interest Coverage too high?
GlaxoSmithKline Pharmaceuticals' current Interest Coverage of 553.70 is 20% above median its 10-year median of 461.38. Over the past 10 years, this metric has ranged from a low of 102.65 to a high of 2,519.80. The Drug Manufacturers industry median Interest Coverage is 12.77. GlaxoSmithKline Pharmaceuticals' value of 553.70 is 4237.6% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #66 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #66 out of 684 companies for Interest Coverage. This places GlaxoSmithKline Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.77. GlaxoSmithKline Pharmaceuticals' value of 553.70 is 4237.6% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own Interest Coverage has ranged from 102.65 to 2,519.80 over the past decade. While the company's 10-year median is 461.38 vs. the industry median of 12.77, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current Interest Coverage of 553.70 is 4237.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Interest Coverage is 553.70, which is 20% above median its own 10-year median of 461.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,610.20, compared to a current price of ₹2,354.80 — trading 9.8% below its estimated fair value. The current Interest Coverage is 553.70, which is 20% above median its 10-year median of 461.38 and 4237.6% above the Drug Manufacturers industry median of 12.77. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Interest Coverage is 553.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,354.80 is trading 9.8% below its estimated GF Value™ of ₹2,610.20.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:GLAXO:
Interest Coverage: 553.70 (20% above median its 10-year median of 461.38)
GF Value™: ₹2,610.20 vs. price of ₹2,354.80 (9.8% below fair value)
Industry Position: 4237.6% above the Drug Manufacturers median (#66 of 684)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
